Artiva Biotherapeutics (NASDAQ:ARTV) Downgraded by Wedbush to Neutral

Artiva Biotherapeutics (NASDAQ:ARTV) was downgraded by equities research analysts at Wedbush from an “outperform” rating to a “neutral” rating in a research note issued on Tuesday, MarketBeat reports. They currently have a $4.00 price target on the stock. Wedbush‘s target price points to a potential downside of 6.32% from the company’s previous close.

A number of other equities analysts have also issued reports on the company. Wall Street Zen upgraded Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Monday, October 19th. HC Wainwright restated a “buy” rating on shares of Artiva Biotherapeutics in a research note on Friday, October 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $40.00 target price on shares of Artiva Biotherapeutics in a research note on Friday, October 2nd. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $30.00.

Artiva Biotherapeutics Trading Down 30.7%

Shares of ARTV traded down $1.89 during midday trading on Tuesday, hitting $4.27. 8,646,973 shares of the company’s stock traded hands, compared to its average volume of 436,190. Artiva Biotherapeutics has a 1 year low of $2.96 and a 1 year high of $14.53. The firm’s fifty day moving average is $8.55 and its 200-day moving average is $7.97. The stock has a market capitalization of $208.76 million, a price-to-earnings ratio of -1.29 and a beta of 2.40.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.63). On average, equities research analysts anticipate that Artiva Biotherapeutics will post -2.62 EPS for the current year.

Insider Buying and Selling

In related news, CEO Fred Aslan sold 23,463 shares of Artiva Biotherapeutics stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $7.20, for a total value of $168,933.60. Following the sale, the chief executive officer directly owned 1,519,606 shares in the company, valued at approximately $10,941,163.20. The trade was a 1.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Jennifer Bush sold 8,370 shares of the business’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $6.84, for a total value of $57,250.80. Following the transaction, the chief operating officer owned 366,159 shares in the company, valued at approximately $2,504,527.56. This represents a 2.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 137,048 shares of company stock worth $1,086,167 in the last quarter. 1.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Artiva Biotherapeutics

Institutional investors have recently added to or reduced their stakes in the stock. 5AM Venture Management LLC purchased a new stake in shares of Artiva Biotherapeutics during the 2nd quarter valued at approximately $22,827,049. Blue Owl Capital Holdings LP purchased a new stake in shares of Artiva Biotherapeutics during the 2nd quarter valued at approximately $8,483,000. BlackRock Inc. purchased a new stake in shares of Artiva Biotherapeutics during the 2nd quarter valued at approximately $6,739,000. Nantahala Capital Management LLC purchased a new stake in shares of Artiva Biotherapeutics during the 2nd quarter valued at approximately $2,910,000. Finally, Alyeska Investment Group L.P. raised its position in shares of Artiva Biotherapeutics by 173.6% during the 2nd quarter. Alyeska Investment Group L.P. now owns 273,615 shares of the company’s stock valued at $2,654,000 after buying an additional 173,615 shares during the period.

More Artiva Biotherapeutics News

Here are the key news stories impacting Artiva Biotherapeutics this week:

• Positive Sentiment: Artiva reported approximately $319.1 million in cash, cash equivalents and investments as of September 30, 2026. The company is evaluating strategic alternatives and has hired Leerink Partners as a financial adviser, potentially creating value through a partnership, asset sale or other transaction. Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK
• Neutral Sentiment: Trading in ARTV was temporarily halted for pending news before the strategic update was released, reflecting the material nature of the announcement. Trading Halt Report
• Negative Sentiment: Artiva halted further development of AlloNK, including its planned Phase 3 rheumatoid arthritis trial, after longer-term data showed that the treatment’s clinical response was not durable enough to meet the company’s requirements. This eliminates the program that was central to the company’s investment thesis. Artiva Biotherapeutics Ends AlloNK Program, Explores Strategic Options
• Negative Sentiment: The company disclosed two recent Grade 5 events, or patient deaths, in the program. One involved leukoencephalopathy assessed as likely related to fludarabine toxicity, while the other was assessed as unrelated to study treatment. The safety events increase regulatory and investor concerns even though the company said one death was not treatment-related. Artiva discontinues cell therapy after two patient deaths, cuts workforce by 94%
• Negative Sentiment: Artiva plans to reduce its workforce by approximately 94%, signaling a near-term restructuring and a substantial reduction in internal development capacity. Analysts responded with downgrades: Needham moved from Buy to Hold, while Wedbush cut its rating from Outperform to Neutral and set a $4.00 price target. Artiva Biotherapeutics Discontinues Development of AlloNK

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company developing off-the-shelf, allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s approach is intended to provide readily available cell-based treatments that can be manufactured in advance and administered without using each patient’s own cells.

Artiva’s lead product candidate is AlloNK, also known as AB-101, an allogeneic NK cell therapy derived from umbilical cord blood. The company is evaluating AlloNK in combination with antibody treatments, including rituximab, for conditions such as B-cell malignancies and autoimmune diseases.